Infinity Pharma (INFI) Received its Third Buy in a Row

By Ryan Adsit

After B.Riley FBR and Oppenheimer gave Infinity Pharma (NASDAQ: INFI) a Buy rating last month, the company received another Buy, this time from JonesTrading. Analyst Soumit Roy reiterated a Buy rating on Infinity Pharma today. The company’s shares closed last Friday at $0.89.

According to TipRanks.com, Roy is a 5-star analyst with an average return of 29.1% and a 50.0% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Monopar Therapeutics Inc.

Currently, the analyst consensus on Infinity Pharma is a Strong Buy with an average price target of $2.50, a 182.6% upside from current levels. In a report released today, Oppenheimer also assigned a Buy rating to the stock with a $3.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.68 and a one-year low of $0.60. Currently, Infinity Pharma has an average volume of 543.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.